Phase 2 N=71 Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness
Prostate Cancer
Primary: Median Change in Percent Ki-67 From Baseline — 0.5; 1.0; 1.0; 1.0 percentage of tumor cells
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=150 Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndrome · Acute Myelogenous Leukemia
Primary: Participant Response Rates to Decitabine With or Without Valproic Acid in MDS and AML — 22; 29; 6; 9 Percentage of Participants
Phase 2 N=301 LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
Chronic Heart Failure
Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) — 0.83; 1.08 ratio: endpoint/baseline (pg/mL)
Phase 2 N=110 BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Ovarian Neoplasms
Primary: Disease Control Rate (DCR) at Week 24 According to Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1 — 30.6; 43.1 percentage of participants
Phase 2 N=204 Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
Upper Gastrointestinal Mucosal Damage
Primary: Incidence of Subjects With Gastroduodenal Erosions and Ulcers. — 72; 54; 19; 36 participants
Phase 2 N=60 Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Lymphoma
Primary: Progression — 22; 1 participants — p=0.51
Phase 2 N=66 Early Neuromuscular Electrical Stimulation For Quadriceps Muscle Activation Deficits Following Total Knee Replacement
Osteoarthritis
Primary: Change From Baseline in Isometric Quadriceps Muscle Torque 3.5 Weeks Post-operatively — -0.40; -0.67 change in N-m/kg — p=<0.001
Phase 2 N=35 Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Brain and Central Nervous System Tumors
Primary: Maximum Tolerated Dose (Phase I) — 1700; 1700; 1700 mg/day x 5 days
Phase 2 N=167 MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
Recurrent Melanoma · Stage III Skin Melanoma · Stage IV Skin Melanoma
Primary: Anti-tumor Response Defined as Either a CR, PR, or SD as Defined by RECIST — 1; 8; 6 participants
Phase 2 N=39 Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
Gastrointestinal Stromal Tumors
Primary: Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease — 52.6 Percentage of Participants
Phase 2 N=33 Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
Estrogen Receptor-positive Breast Cancer · Recurrent Breast Cancer · Stage IIIB Breast Cancer
Primary: Clinical Benefit Rate (CBR) (CR Rate, PR Rate, and SD) — 11; 5; 0 participants
Phase 2 N=32 A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers
Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of LCZ696 Analytes (AHU377, LBQ657, and…
Phase 2 N=10 A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
Leukaemia, Lymphocytic, Chronic
Primary: Number of Participants Who Developed Toxicity Requiring Discontinuation From Study Treatment During Cycle 1 — 0 Participants
Phase 2 N=98 Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects
Hypertension · Concurrent Obesity
Primary: Change From Baseline in Insulin Sensitivity Index — 0.192; 0.065 ug/kg*min/(mmol/L*pmol/L)
Phase 2 N=1,328 Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) — -9.97; -12.92; -13.63; -9.14 mmHg